Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | F13A1 | P00488 | 1/20 | 0.61 |
| ▸ | ESRRG | P62508 | 3/20 | 0.53 |
| ▸ | ESRRB | O95718 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.48 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475970 | 0.91 | KDM4E (0.51) | KDM4EF13A1ESRRGESRRBSMN1; SMN2 | |
| SCHEMBL8699335 | 0.90 | POLB (0.55) | KDM4EF13A1ESRRGSMN1; SMN2ALDH1A1 | |
| SCHEMBL23346356 | 0.86 | TRPV1 (0.50) | KDM4EF13A1ESRRGESRRBSMN1; SMN2 | |
| SCHEMBL4179064 | 0.86 | HPGD (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1PLAAT3 | |
| SCHEMBL5553483 | 0.84 | PLAAT3 (0.58) | SMN1; SMN2ALDH1A1POLBPLAAT3PLAAT5 | |
| SCHEMBL4700346 | 0.84 | ESRRG (0.54) | KDM4EF13A1ESRRGSMN1; SMN2GFER | |
| SCHEMBL419646 | 0.84 | CNR1 (0.50) | SMN1; SMN2ALDH1A1POLBPLAAT3PLAAT5 | |
| SCHEMBL1094537 | 0.84 | CNR1 (0.57) | SMN1; SMN2NPC1CYP1A2GAACYP2D6 | |
| SCHEMBL4702861 | 0.84 | ALDH1A1 (0.47) | KDM4EF13A1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL14141265 | 0.84 | NPC1 (0.59) | KDM4EF13A1SMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12188086-B2 | Nucleotide analogues and use thereof for nucleic acid sequencing and analysis preliminary class | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20210139976-A1 | NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210139976-A1 | NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3765028-A1 | NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS | The Trustees of Columbia University in the City of New York (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112218640-A | Nucleotide analogs and their use in nucleic acid sequencing and analysis | 哥伦比亚大学董事会 | 2021-01-12 | — | — | CN | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2019178393-A9 | NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019178393-A1 | NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019178547-A1 | BENZOXAZINE POLYMERS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-1042287-B1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6337344-B1 | ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-08 | — | — | US | disclosed |
| EP-0781126-B1 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON SPA (IT) | 2001-12-12 | — | — | EP | disclosed |
| EP-1042287-A1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| US-5773469-A | Diaryl antimicrobial agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997048674-A1 | DIARYL ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
| US-5674909-A | FOR TREATMENT OF CARDIOVASCULAR DISORDERS | ZAMBON GROUP (IT) | 1997-10-07 | — | — | US | disclosed |
| EP-0781126-A2 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.p.A. (IT) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008228-A2 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.P.A. (IT) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | KDM4E 3593/4885F13A1 3513/4885ESRRG 3415/4885 |
| US-12188086-B2 | Nucleotide analogues and use thereof for nucleic acid sequencing and analysis preliminary class | NUDT1, NT5C3B, RNGTT | KDM4E 3837/4885F13A1 2875/4885ESRRG 4221/4885 |
| US-20210139976-A1 | NUCLEOTIDE ANALOGUES AND USE THEREOF FOR NUCLEIC ACID SEQUENCING AND ANALYSIS | NUDT1, NT5C3B, RNGTT | KDM4E 4107/4885F13A1 3863/4885ESRRG 4041/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | KDM4E 3595/4885F13A1 3499/4885ESRRG 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.